Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis.

BACKGROUND: Dupilumab has shown to be an effective and safe treatment for patients with moderate-to-severe atopic dermatitis (AD). OBJECTIVE: To evaluate the predictive factors of response (PRF) in patients with moderate-to-severe AD treated with dupilumab. METHODS: Observational, retrospective and...

Descripción completa

Detalles Bibliográficos
Autores: Melé-Ninot G, Curto-Barredo L, Bonfill-Ortí M, Expósito-Serrano V, Munera-Campos M, Figueras Nart I, Riquelme-Mc Loughlin C, Gómez-Armayones S, Spertino J, Serra-Baldrich E
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2023
País:España
Institución:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p4281
Acceso en línea:https://i3pt.portalinvestigacion.com/publicaciones/4281
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85178882781&doi=10.1111%2fajd.14196&partnerID=40&md5=c5b11b692ff4c162f271c296a5eb2952
Access Level:acceso abierto
Palabra clave:atopic dermatitis
dupilumab
predictive factors
treatment
id ES_fd67b44b8a565c12f8f88e27cd2c4c77
oai_identifier_str oai:i3pt.fundanetsuite.com:p4281
network_acronym_str ES
network_name_str España
repository_id_str
spelling Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis.Melé-Ninot GCurto-Barredo LBonfill-Ortí MExpósito-Serrano VMunera-Campos MFigueras Nart IRiquelme-Mc Loughlin CGómez-Armayones SSpertino JSerra-Baldrich Eatopic dermatitisdupilumabpredictive factorstreatmentBACKGROUND: Dupilumab has shown to be an effective and safe treatment for patients with moderate-to-severe atopic dermatitis (AD). OBJECTIVE: To evaluate the predictive factors of response (PRF) in patients with moderate-to-severe AD treated with dupilumab. METHODS: Observational, retrospective and multicentre study conducted on adult patients diagnosed with moderate-to-severe AD treated with dupilumab, with a post-treatment follow-up of at least 16 weeks. The primary endpoints were EASI-75 and the IGA scale at week 52. RESULTS: A total of 198 patients were included in the analysis. Mean age was 38 ± 15.1 years and 116 (58.6%) were men. The most prevalent AD-predominant phenotypes were flexural eczema (45.3%), head-and-neck eczema (18.2%) and erythroderma (17.7%). At week 52, 140 (86.4%) patients achieved EASI-75 and 119 (93.0%) achieved an improvement in =2 points from baseline in IGA score. Women were 3.6 times more likely to achieve EASI-75 response than men (Odds ratio: 3.58; p = 0.020). While increased body mass index significantly reduced the probability of obtaining an improvement of =2 points in the IGA scale at week 52 (odds ratio: 0.88; p = 0.049). CONCLUSIONS: Dupilumab was an effective treatment in patients with moderate-to-severe AD. Additionally, sex and body mass index were significantly associated with achieving EASI-75 and an improvement of =2 points in the IGA scale, respectively, at week 52.WILEY2023info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://i3pt.portalinvestigacion.com/publicaciones/4281https://www.scopus.com/inward/record.uri?eid=2-s2.0-85178882781&doi=10.1111%2fajd.14196&partnerID=40&md5=c5b11b692ff4c162f271c296a5eb2952AUSTRALASIAN JOURNAL OF DERMATOLOGYISSN: 00048380ISSNe: 14400960reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulíinstname:Institut d'Investigació i Innovació Parc Taulí (I3PT)Inglésinfo:eu-repo/semantics/openAccessoai:i3pt.fundanetsuite.com:p42812026-06-21T15:30:37Z
dc.title.none.fl_str_mv Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis.
title Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis.
spellingShingle Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis.
Melé-Ninot G
atopic dermatitis
dupilumab
predictive factors
treatment
title_short Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis.
title_full Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis.
title_fullStr Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis.
title_full_unstemmed Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis.
title_sort Assessment of potential predictive factors of dupilumab response in patients with moderate-to-severe atopic dermatitis.
dc.creator.none.fl_str_mv Melé-Ninot G
Curto-Barredo L
Bonfill-Ortí M
Expósito-Serrano V
Munera-Campos M
Figueras Nart I
Riquelme-Mc Loughlin C
Gómez-Armayones S
Spertino J
Serra-Baldrich E
author Melé-Ninot G
author_facet Melé-Ninot G
Curto-Barredo L
Bonfill-Ortí M
Expósito-Serrano V
Munera-Campos M
Figueras Nart I
Riquelme-Mc Loughlin C
Gómez-Armayones S
Spertino J
Serra-Baldrich E
author_role author
author2 Curto-Barredo L
Bonfill-Ortí M
Expósito-Serrano V
Munera-Campos M
Figueras Nart I
Riquelme-Mc Loughlin C
Gómez-Armayones S
Spertino J
Serra-Baldrich E
author2_role author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv atopic dermatitis
dupilumab
predictive factors
treatment
topic atopic dermatitis
dupilumab
predictive factors
treatment
description BACKGROUND: Dupilumab has shown to be an effective and safe treatment for patients with moderate-to-severe atopic dermatitis (AD). OBJECTIVE: To evaluate the predictive factors of response (PRF) in patients with moderate-to-severe AD treated with dupilumab. METHODS: Observational, retrospective and multicentre study conducted on adult patients diagnosed with moderate-to-severe AD treated with dupilumab, with a post-treatment follow-up of at least 16 weeks. The primary endpoints were EASI-75 and the IGA scale at week 52. RESULTS: A total of 198 patients were included in the analysis. Mean age was 38 ± 15.1 years and 116 (58.6%) were men. The most prevalent AD-predominant phenotypes were flexural eczema (45.3%), head-and-neck eczema (18.2%) and erythroderma (17.7%). At week 52, 140 (86.4%) patients achieved EASI-75 and 119 (93.0%) achieved an improvement in =2 points from baseline in IGA score. Women were 3.6 times more likely to achieve EASI-75 response than men (Odds ratio: 3.58; p = 0.020). While increased body mass index significantly reduced the probability of obtaining an improvement of =2 points in the IGA scale at week 52 (odds ratio: 0.88; p = 0.049). CONCLUSIONS: Dupilumab was an effective treatment in patients with moderate-to-severe AD. Additionally, sex and body mass index were significantly associated with achieving EASI-75 and an improvement of =2 points in the IGA scale, respectively, at week 52.
publishDate 2023
dc.date.none.fl_str_mv 2023
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://i3pt.portalinvestigacion.com/publicaciones/4281
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85178882781&doi=10.1111%2fajd.14196&partnerID=40&md5=c5b11b692ff4c162f271c296a5eb2952
url https://i3pt.portalinvestigacion.com/publicaciones/4281
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85178882781&doi=10.1111%2fajd.14196&partnerID=40&md5=c5b11b692ff4c162f271c296a5eb2952
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv WILEY
publisher.none.fl_str_mv WILEY
dc.source.none.fl_str_mv AUSTRALASIAN JOURNAL OF DERMATOLOGY
ISSN: 00048380
ISSNe: 14400960
reponame:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
instname:Institut d'Investigació i Innovació Parc Taulí (I3PT)
instname_str Institut d'Investigació i Innovació Parc Taulí (I3PT)
reponame_str r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
collection r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425536672989184
score 15,81155

Similares en LA Referencia